Matches in Wikidata for { <http://www.wikidata.org/entity/Q85077949> ?p ?o ?g. }
- Q85077949 description "2011 nî lūn-bûn" @default.
- Q85077949 description "2011 թվականի հոկտեմբերի 11-ին հրատարակված գիտական հոդված" @default.
- Q85077949 description "2011年の論文" @default.
- Q85077949 description "2011年学术文章" @default.
- Q85077949 description "2011年学术文章" @default.
- Q85077949 description "2011年学术文章" @default.
- Q85077949 description "2011年学术文章" @default.
- Q85077949 description "2011年学术文章" @default.
- Q85077949 description "2011年学术文章" @default.
- Q85077949 description "2011年學術文章" @default.
- Q85077949 description "2011年學術文章" @default.
- Q85077949 description "2011年學術文章" @default.
- Q85077949 description "2011年學術文章" @default.
- Q85077949 description "2011年學術文章" @default.
- Q85077949 description "2011년 논문" @default.
- Q85077949 description "article científic" @default.
- Q85077949 description "article scientific" @default.
- Q85077949 description "article scientifique" @default.
- Q85077949 description "articol științific" @default.
- Q85077949 description "articolo scientifico" @default.
- Q85077949 description "artigo científico" @default.
- Q85077949 description "artigo científico" @default.
- Q85077949 description "artigo científico" @default.
- Q85077949 description "artikel ilmiah" @default.
- Q85077949 description "artikull shkencor" @default.
- Q85077949 description "artikulong pang-agham" @default.
- Q85077949 description "artykuł naukowy" @default.
- Q85077949 description "artículo científico publicado en 2011" @default.
- Q85077949 description "artículu científicu" @default.
- Q85077949 description "bilimsel makale" @default.
- Q85077949 description "bài báo khoa học" @default.
- Q85077949 description "naučni članak" @default.
- Q85077949 description "scienca artikolo" @default.
- Q85077949 description "scientific article published on 11 October 2011" @default.
- Q85077949 description "scientific article published on 11 October 2011" @default.
- Q85077949 description "scientific article published on 11 October 2011" @default.
- Q85077949 description "teaduslik artikkel" @default.
- Q85077949 description "tieteellinen artikkeli" @default.
- Q85077949 description "tudományos cikk" @default.
- Q85077949 description "vedecký článok" @default.
- Q85077949 description "vetenskaplig artikel" @default.
- Q85077949 description "videnskabelig artikel udgivet 11. oktober 2011" @default.
- Q85077949 description "vitenskapelig artikkel" @default.
- Q85077949 description "vitskapeleg artikkel" @default.
- Q85077949 description "vědecký článek" @default.
- Q85077949 description "wetenschappelijk artikel" @default.
- Q85077949 description "wissenschaftlicher Artikel" @default.
- Q85077949 description "επιστημονικό άρθρο" @default.
- Q85077949 description "мақолаи илмӣ" @default.
- Q85077949 description "наукова стаття, опублікована в жовтні 2011" @default.
- Q85077949 description "научна статия" @default.
- Q85077949 description "научная статья" @default.
- Q85077949 description "научни чланак" @default.
- Q85077949 description "научни чланак" @default.
- Q85077949 description "מאמר מדעי" @default.
- Q85077949 description "مقالة علمية نشرت في 11 أكتوبر 2011" @default.
- Q85077949 description "১১ অক্টোবর ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q85077949 description "บทความทางวิทยาศาสตร์" @default.
- Q85077949 description "სამეცნიერო სტატია" @default.
- Q85077949 name "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br" @default.
- Q85077949 name "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br" @default.
- Q85077949 type Item @default.
- Q85077949 label "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br" @default.
- Q85077949 label "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br" @default.
- Q85077949 prefLabel "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br" @default.
- Q85077949 prefLabel "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br" @default.
- Q85077949 P1433 Q85077949-08C6E36D-230B-432C-AD81-BA9032AE2322 @default.
- Q85077949 P1476 Q85077949-41C693C5-FE92-45DD-A0A5-EA11C8A905DE @default.
- Q85077949 P2093 Q85077949-26E53863-9471-4046-85A7-05B46A24AF92 @default.
- Q85077949 P2093 Q85077949-2AF0C684-FA96-47D0-96F1-9129834B9614 @default.
- Q85077949 P2093 Q85077949-AF9A9A0D-9C29-4033-AAF8-D050F6A523CA @default.
- Q85077949 P2093 Q85077949-C634F7E9-8A7C-4657-8C5D-3FE28EA30D87 @default.
- Q85077949 P2093 Q85077949-CCC2CCDD-A1F4-49E5-8B51-9E62D47B38EF @default.
- Q85077949 P304 Q85077949-50D6062E-4D3D-4748-87F1-0708196BBBFE @default.
- Q85077949 P31 Q85077949-1DF3BCE6-697F-4B22-BDD7-82B4E6E0179F @default.
- Q85077949 P356 Q85077949-29F07807-6195-4043-A618-FFA40DE292D4 @default.
- Q85077949 P433 Q85077949-65F0E5EE-4C46-4F48-9EA4-A82F63FFD970 @default.
- Q85077949 P478 Q85077949-F5F08A22-C4E6-42DD-8FF6-700766C81587 @default.
- Q85077949 P50 Q85077949-3CB32459-BCB5-4FD0-8C70-3C1E16F6200A @default.
- Q85077949 P50 Q85077949-AB36BEEA-C9AC-4F0E-AA27-8163C1A79619 @default.
- Q85077949 P577 Q85077949-07074531-73E3-4EE9-8355-B6EF401B93F8 @default.
- Q85077949 P698 Q85077949-83214785-1F59-4267-A0D4-C2CCD6001441 @default.
- Q85077949 P921 Q85077949-063AED8B-1D06-478E-8CEC-AB7E22C546CE @default.
- Q85077949 P921 Q85077949-88518847-D33D-4A5E-B11C-0C45D0476938 @default.
- Q85077949 P356 JCO.2010.34.1255 @default.
- Q85077949 P698 21990397 @default.
- Q85077949 P1433 Q400292 @default.
- Q85077949 P1476 "RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer" @default.
- Q85077949 P2093 "Adam M Brufsky" @default.
- Q85077949 P2093 "Raji Swamy" @default.
- Q85077949 P2093 "Sara Hurvitz" @default.
- Q85077949 P2093 "Vicente Valero" @default.
- Q85077949 P2093 "Vincent O'Neill" @default.
- Q85077949 P304 "4286-4293" @default.
- Q85077949 P31 Q13442814 @default.
- Q85077949 P356 "10.1200/JCO.2010.34.1255" @default.
- Q85077949 P433 "32" @default.
- Q85077949 P478 "29" @default.
- Q85077949 P50 Q18389345 @default.
- Q85077949 P50 Q55975497 @default.